Drugs / Trifluridine/Tipiracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04072445 | Oct 2019 → Aug 2021 | distal biliary tract carcinoma, gallbladder cancer, intrahepatic bile duct cancer | Mayo Clinic | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil | “Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.” PMID 37339254 ↗ Oct 2023 |
| Action | Inhibit | “may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.” NCT04072445 ↗ |
| Route | Oral | “Given PO” NCT04072445 ↗ |